BidaskClub upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a sell rating to a hold rating in a research note released on Friday.

ATRA has been the subject of several other reports. ValuEngine raised Atara Biotherapeutics from a buy rating to a strong-buy rating in a report on Wednesday, May 2nd. Zacks Investment Research raised Atara Biotherapeutics from a sell rating to a hold rating in a report on Wednesday, June 27th. Jefferies Financial Group reaffirmed a buy rating and issued a $45.00 price objective on shares of Atara Biotherapeutics in a report on Friday, August 3rd. Canaccord Genuity reiterated a buy rating and issued a $70.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, May 8th. Finally, Citigroup decreased their price target on Atara Biotherapeutics from $25.00 to $23.00 and set a sell rating on the stock in a research note on Monday, June 11th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Atara Biotherapeutics presently has an average rating of Hold and an average price target of $43.17.

NASDAQ:ATRA opened at $37.60 on Friday. The company has a market cap of $1.72 billion, a P/E ratio of -9.40 and a beta of 2.55. Atara Biotherapeutics has a 1-year low of $12.65 and a 1-year high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.17). analysts predict that Atara Biotherapeutics will post -4.58 earnings per share for the current year.

In related news, CEO Isaac E. Ciechanover sold 8,800 shares of the business’s stock in a transaction on Wednesday, June 6th. The stock was sold at an average price of $48.56, for a total transaction of $427,328.00. Following the sale, the chief executive officer now owns 812,613 shares in the company, valued at approximately $39,460,487.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Carol Giltner Gallagher sold 2,500 shares of the business’s stock in a transaction on Monday, June 18th. The stock was sold at an average price of $44.78, for a total value of $111,950.00. Following the sale, the director now owns 110,592 shares in the company, valued at approximately $4,952,309.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 109,775 shares of company stock worth $4,368,186. Corporate insiders own 10.60% of the company’s stock.

A number of hedge funds have recently modified their holdings of ATRA. Redmile Group LLC grew its position in Atara Biotherapeutics by 50.4% during the 1st quarter. Redmile Group LLC now owns 4,236,017 shares of the biotechnology company’s stock worth $165,205,000 after acquiring an additional 1,420,029 shares during the last quarter. BlackRock Inc. grew its position in Atara Biotherapeutics by 45.0% during the 1st quarter. BlackRock Inc. now owns 2,844,441 shares of the biotechnology company’s stock worth $110,934,000 after acquiring an additional 882,180 shares during the last quarter. Federated Investors Inc. PA bought a new stake in Atara Biotherapeutics during the 1st quarter worth $18,585,000. PointState Capital LP bought a new stake in Atara Biotherapeutics during the 1st quarter worth $11,583,000. Finally, Artal Group S.A. grew its position in Atara Biotherapeutics by 25.0% during the 1st quarter. Artal Group S.A. now owns 1,250,000 shares of the biotechnology company’s stock worth $48,750,000 after acquiring an additional 250,000 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Story: How Short Selling Works

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.